Big Upgrade for Rapt Therapeutics’ Allergy Drug RPT904

Leerink Partners dramatically upgraded Rapt Therapeutics stock based on the strong outlook for RPT904, a leading drug candidate designed to treat severe allergies, including food allergy, by improving on the current standard treatment, Xolair.